References
- Datamonitor, Stakeholder Insight: Prostate Cancer – hormone-refractory patients still waiting for treatment breakthroughs. (2007).
- de Bono J : Prostate Cancer, An Unmet Clinical Need. Institute of Cancer Research Annual Research Report (2006).
- Holdenrieder S , StieberP: Apoptotic markers in cancer.Clin. Biochem.37 , 605– 617 (2004).
- Holdenrieder S , EichhornP, BeuersU et al.: Nucleosomal DNA fragments in autoimmune diseases.Ann. NY Acad. Sci.1075 , 318–327 (2006).
- Swaminathan R , ButtAN: Circulating nucleic acids in plasma and serum – recent developments.Ann. NY Acad. Sci.1075 , 1–9 (2006).
- Fraga MF , BallestarE, Villar-GareaA: Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.Nat. Genet.37 , 391–400 (2005).
- Kurdistani SK : Histone modifications as markers of cancer prognosis: a cellular view.Br. J. Cancer97 , 1–5 (2007).
- Seligson DB , HorvathS, ShiT et al.: Global histone modification patterns predict risk of prostate cancer recurrence.Nature435 , 1262–1266 (2005).
- Mohamed MA , GreifPA, DiamondJ et al.: Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma.BJU Int.99 , 908–915 (2007).
- Migliaccio A , VarricchioL, de Falco A et al.: Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene26(46) , 6619–6629 (2007).
Patent
- WO 2003/070894: Detection of histone modifications in cell-free nucleosome. US Patent 20070160989 .